Study details
Enrolling now
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Eli Lilly and Company
NCT IDNCT07426380ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–85
Locations
2 sites in FL
About this study
This Phase 1 study is focused on people with end stage kidney disease. The primary outcome being measured is PK: Maximum Observed Drug Concentration (Cmax) of LY3841136.
Based on ClinicalTrials.gov records.
PhasePhase 1
Primary goalPK: Maximum Observed Drug Concentration (Cmax) of LY3841136
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: PK: Maximum Observed Drug Concentration (Cmax) of LY3841136, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136
Body systems
Renal